Daehwa Pharma Renews Push for Domestic Insurance Coverage of Oral Cancer Drug Liporaxel After Decade-Long Hurdle

Hee Chan Kim Reporter

jujui@hanmail.net | 2026-11-20 06:37:02


SEOUL — Daehwa Pharmaceutical is making a renewed bid to secure national health insurance reimbursement in South Korea for Liporaxel, its oral chemotherapy drug, nearly a decade after the treatment first received regulatory approval. Following three unsuccessful pricing negotiations in the past, the company is looking to replicate the drug's recent commercial momentum in China within its home market.

On November 11, the Cancer Disease Review Committee under the Health Insurance Review and Assessment Service (HIRA) established reimbursement standards for Liporaxel across two indications: advanced, metastatic, or locally recurrent gastric cancer, and first-line treatment for recurrent or metastatic HER2-negative breast cancer.

Liporaxel is an incrementally modified drug that reformulates paclitaxel—the active ingredient in the blockbuster intravenous chemotherapy Taxol—into an oral liquid. While it gained Korean regulatory approval as the world's first oral paclitaxel treatment for gastric cancer in September 2016 and added the breast cancer indication in May of this year, it has remained non-reimbursed locally. Previous attempts to secure coverage in 2018, 2019, and 2020 stalled after health authorities demanded lower pricing than Daehwa Pharma was willing to accept, arguing there was insufficient evidence to justify a premium over existing therapies.

Commercial Breakthrough in China

While domestic pricing talks hit an impasse, Liporaxel found commercial traction in China. Under a $25 million licensing deal signed in 2017, local partner RMX Biopharma (now Haihe Biopharma) conducted Phase 3 clinical trials and secured marketing approval from China’s National Medical Products Administration (NMPA) in September 2024.

Following its inclusion in China’s National Reimbursement Drug List (NRDL) at 1,208 yuan per 30mL vial, insured sales began in January of this year. According to regulatory filings from Haihe Biopharma, sales volume surpassed 40,000 boxes in the first half of the year alone—nearly five times the full-year volume of 8,300 boxes recorded in 2025. Last month, Chinese regulators also expanded the drug's label to include second- and third-line breast cancer treatments, granting it a broader scope than in South Korea.

Domestic Reimbursement Key to Financial Turnaround

Because Daehwa Pharma retains domestic commercial rights, securing local reimbursement is viewed as critical for breaking out of its current earnings stagnation. For the first nine months of the year, the company posted consolidated revenue of 113.6 billion won, up 3.9% year-on-year, while operating profit remained flat at 2.5 billion won. In the third quarter, revenue dipped 3.9% and operating income swung to a loss of 1.3 billion won.

Industry observers note that conditions for the current pricing negotiation are more favorable than in previous rounds. The addition of the breast cancer indication expands the eligible patient pool, giving the company greater leverage in volume-based pricing discussions. Furthermore, Daehwa Pharma plans to utilize South Korea's flexible drug pricing agreement system—which adjusts financial burdens based on actual usage—and point to China's reimbursement price as a benchmark.

The company also faces pressure to recoup roughly 27.5 billion won in intangible development assets tied largely to Liporaxel. Although Daehwa Pharma generated approximately 9.7 billion won in supply revenue from China during the first half of the year, shipments paused in the third quarter due to internal inspections. A company official stated that orders for the Chinese market are expected to normalize in the fourth quarter, adding that no firm timeline has been set yet for product approval in Vietnam, where the firm recently signed an exclusive licensing and distribution agreement with Singapore's Axella Bioscience.

[ⓒ Global Economic Times. 무단전재-재배포 금지]

WEEKLY HOT